The prevalence of anti-MDA5 antibody in our DM/CADM patients was 20.7%, which is consistent with other studies from China (15–20%), but higher than that of patients from Europe and North American (4–7%) [15–17]. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.